Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Yee KW, Storring JM, Buckstein R, Wells RA, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza AM, Ivy SP, Schuh AC. Yee KW, et al. Among authors: ivy sp. Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22. Leuk Lymphoma. 2014. PMID: 24611649 Clinical Trial. No abstract available.
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. Sridhar SS, et al. Among authors: ivy sp. Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26. Invest New Drugs. 2013. PMID: 23354849 Clinical Trial.
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E. Richter S, et al. Among authors: ivy sp. Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5. Invest New Drugs. 2014. PMID: 23645447 Free PMC article. Clinical Trial.
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL. Diaz-Padilla I, et al. Among authors: ivy sp. Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5. Epub 2013 Jul 17. Invest New Drugs. 2013. PMID: 23860641 Free PMC article. Clinical Trial.
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ. Sahebjam S, et al. Among authors: ivy sp. Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18. Br J Cancer. 2013. PMID: 23868004 Free PMC article. Clinical Trial.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM. Diaz-Padilla I, et al. Among authors: ivy sp. Gynecol Oncol. 2015 May;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005. Epub 2015 Mar 11. Gynecol Oncol. 2015. PMID: 25769658 Clinical Trial.
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. Hirte H, et al. Among authors: ivy sp. Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17. Gynecol Oncol. 2015. PMID: 25895616 Clinical Trial.
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ. Spreafico A, et al. Among authors: ivy sp. Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3. Invest New Drugs. 2014. PMID: 24788563 Free PMC article. Clinical Trial.
171 results